At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 10 enrolled
Drug / intervention
Lucentisdrug
Likely dose
Lucentis 0.3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis
In Brief
A Phase 4 clinical trial evaluating Lucentis for Diabetic Macular Edema. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The protocol will measure a number of cytokines in addition to vascular endothelial growth factor in response to 0.3mg Lucentis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema
CountriesUnited States
CollaboratorsGenentech, Inc., Michigan State University
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartApr 2017
Primary CompletionDec 2017
Study CompletionFeb 2018
TodayJul 2026
First PostedMar 31, 2017
Enrollment StartApr 19, 2017
Primary CompletionDec 6, 2017
Study CompletionFeb 2, 2018
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.3 years ago
Interventions
Lucentisdrug
0.3mg Lucentis